nodes	percent_of_prediction	percent_of_DWPC	metapath
Apraclonidine—Dizziness—Cladribine—multiple sclerosis	0.00168	0.00185	CcSEcCtD
Apraclonidine—Erythema—Prednisolone—multiple sclerosis	0.00168	0.00185	CcSEcCtD
Apraclonidine—Oedema—Mitoxantrone—multiple sclerosis	0.00167	0.00184	CcSEcCtD
Apraclonidine—Infection—Mitoxantrone—multiple sclerosis	0.00166	0.00183	CcSEcCtD
Apraclonidine—Eye disorder—Methylprednisolone—multiple sclerosis	0.00166	0.00182	CcSEcCtD
Apraclonidine—Bradycardia—Dexamethasone—multiple sclerosis	0.00164	0.0018	CcSEcCtD
Apraclonidine—Bradycardia—Betamethasone—multiple sclerosis	0.00164	0.0018	CcSEcCtD
Apraclonidine—Abdominal pain—Azathioprine—multiple sclerosis	0.00164	0.0018	CcSEcCtD
Apraclonidine—Skin disorder—Mitoxantrone—multiple sclerosis	0.00163	0.00178	CcSEcCtD
Apraclonidine—Irritability—Methotrexate—multiple sclerosis	0.00162	0.00178	CcSEcCtD
Apraclonidine—Vomiting—Cladribine—multiple sclerosis	0.00162	0.00178	CcSEcCtD
Apraclonidine—Haemorrhage—Betamethasone—multiple sclerosis	0.00161	0.00177	CcSEcCtD
Apraclonidine—Haemorrhage—Dexamethasone—multiple sclerosis	0.00161	0.00177	CcSEcCtD
Apraclonidine—Angiopathy—Methylprednisolone—multiple sclerosis	0.00161	0.00177	CcSEcCtD
Apraclonidine—Dermatitis—Cladribine—multiple sclerosis	0.0016	0.00176	CcSEcCtD
Apraclonidine—Mediastinal disorder—Methylprednisolone—multiple sclerosis	0.0016	0.00175	CcSEcCtD
Apraclonidine—Headache—Cladribine—multiple sclerosis	0.0016	0.00175	CcSEcCtD
Apraclonidine—Arrhythmia—Triamcinolone—multiple sclerosis	0.00159	0.00174	CcSEcCtD
Apraclonidine—Vision blurred—Prednisolone—multiple sclerosis	0.00159	0.00174	CcSEcCtD
Apraclonidine—Arrhythmia—Methylprednisolone—multiple sclerosis	0.00158	0.00174	CcSEcCtD
Apraclonidine—Ill-defined disorder—Prednisolone—multiple sclerosis	0.00156	0.00171	CcSEcCtD
Apraclonidine—Visual impairment—Dexamethasone—multiple sclerosis	0.00155	0.00171	CcSEcCtD
Apraclonidine—Visual impairment—Betamethasone—multiple sclerosis	0.00155	0.00171	CcSEcCtD
Apraclonidine—Mental disorder—Methylprednisolone—multiple sclerosis	0.00155	0.00171	CcSEcCtD
Apraclonidine—Erythema—Triamcinolone—multiple sclerosis	0.00155	0.0017	CcSEcCtD
Apraclonidine—Erythema—Methylprednisolone—multiple sclerosis	0.00154	0.00169	CcSEcCtD
Apraclonidine—Hypersensitivity—Azathioprine—multiple sclerosis	0.00153	0.00167	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Mitoxantrone—multiple sclerosis	0.00152	0.00167	CcSEcCtD
Apraclonidine—Malaise—Prednisolone—multiple sclerosis	0.00152	0.00167	CcSEcCtD
Apraclonidine—Dysgeusia—Triamcinolone—multiple sclerosis	0.00152	0.00166	CcSEcCtD
Apraclonidine—Nausea—Cladribine—multiple sclerosis	0.00151	0.00166	CcSEcCtD
Apraclonidine—Syncope—Prednisolone—multiple sclerosis	0.00151	0.00166	CcSEcCtD
Apraclonidine—Eye disorder—Dexamethasone—multiple sclerosis	0.00151	0.00165	CcSEcCtD
Apraclonidine—Eye disorder—Betamethasone—multiple sclerosis	0.00151	0.00165	CcSEcCtD
Apraclonidine—Paraesthesia—Mitoxantrone—multiple sclerosis	0.0015	0.00165	CcSEcCtD
Apraclonidine—Dyspnoea—Mitoxantrone—multiple sclerosis	0.00149	0.00164	CcSEcCtD
Apraclonidine—Somnolence—Mitoxantrone—multiple sclerosis	0.00149	0.00163	CcSEcCtD
Apraclonidine—Asthma—Methotrexate—multiple sclerosis	0.00147	0.00161	CcSEcCtD
Apraclonidine—Angiopathy—Betamethasone—multiple sclerosis	0.00146	0.00161	CcSEcCtD
Apraclonidine—Angiopathy—Dexamethasone—multiple sclerosis	0.00146	0.00161	CcSEcCtD
Apraclonidine—Fatigue—Mitoxantrone—multiple sclerosis	0.00144	0.00158	CcSEcCtD
Apraclonidine—Arrhythmia—Betamethasone—multiple sclerosis	0.00144	0.00158	CcSEcCtD
Apraclonidine—Arrhythmia—Dexamethasone—multiple sclerosis	0.00144	0.00158	CcSEcCtD
Apraclonidine—Ill-defined disorder—Triamcinolone—multiple sclerosis	0.00144	0.00158	CcSEcCtD
Apraclonidine—Ill-defined disorder—Methylprednisolone—multiple sclerosis	0.00143	0.00157	CcSEcCtD
Apraclonidine—Pain—Mitoxantrone—multiple sclerosis	0.00143	0.00157	CcSEcCtD
Apraclonidine—Constipation—Mitoxantrone—multiple sclerosis	0.00143	0.00157	CcSEcCtD
Apraclonidine—Bradycardia—Prednisone—multiple sclerosis	0.00143	0.00157	CcSEcCtD
Apraclonidine—Diarrhoea—Azathioprine—multiple sclerosis	0.00142	0.00155	CcSEcCtD
Apraclonidine—Discomfort—Prednisolone—multiple sclerosis	0.00142	0.00155	CcSEcCtD
Apraclonidine—Abdominal discomfort—Methotrexate—multiple sclerosis	0.00141	0.00154	CcSEcCtD
Apraclonidine—Haemorrhage—Prednisone—multiple sclerosis	0.0014	0.00154	CcSEcCtD
Apraclonidine—Erythema—Betamethasone—multiple sclerosis	0.0014	0.00154	CcSEcCtD
Apraclonidine—Erythema—Dexamethasone—multiple sclerosis	0.0014	0.00154	CcSEcCtD
Apraclonidine—Malaise—Triamcinolone—multiple sclerosis	0.0014	0.00153	CcSEcCtD
Apraclonidine—Malaise—Methylprednisolone—multiple sclerosis	0.00139	0.00153	CcSEcCtD
Apraclonidine—Syncope—Triamcinolone—multiple sclerosis	0.00139	0.00152	CcSEcCtD
Apraclonidine—Syncope—Methylprednisolone—multiple sclerosis	0.00138	0.00152	CcSEcCtD
Apraclonidine—Feeling abnormal—Mitoxantrone—multiple sclerosis	0.00138	0.00151	CcSEcCtD
Apraclonidine—Oedema—Prednisolone—multiple sclerosis	0.00137	0.00151	CcSEcCtD
Apraclonidine—Dizziness—Azathioprine—multiple sclerosis	0.00137	0.0015	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Mitoxantrone—multiple sclerosis	0.00137	0.0015	CcSEcCtD
Apraclonidine—Abdominal pain—Mitoxantrone—multiple sclerosis	0.00132	0.00145	CcSEcCtD
Apraclonidine—Myalgia—Triamcinolone—multiple sclerosis	0.00132	0.00145	CcSEcCtD
Apraclonidine—Vomiting—Azathioprine—multiple sclerosis	0.00132	0.00144	CcSEcCtD
Apraclonidine—Myalgia—Methylprednisolone—multiple sclerosis	0.00131	0.00144	CcSEcCtD
Apraclonidine—Eye disorder—Prednisone—multiple sclerosis	0.00131	0.00144	CcSEcCtD
Apraclonidine—Infestation NOS—Methotrexate—multiple sclerosis	0.00131	0.00144	CcSEcCtD
Apraclonidine—Infestation—Methotrexate—multiple sclerosis	0.00131	0.00144	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	0.00131	0.00143	CcSEcCtD
Apraclonidine—Dermatitis—Azathioprine—multiple sclerosis	0.0013	0.00143	CcSEcCtD
Apraclonidine—Ill-defined disorder—Dexamethasone—multiple sclerosis	0.0013	0.00143	CcSEcCtD
Apraclonidine—Ill-defined disorder—Betamethasone—multiple sclerosis	0.0013	0.00143	CcSEcCtD
Apraclonidine—Discomfort—Triamcinolone—multiple sclerosis	0.0013	0.00143	CcSEcCtD
Apraclonidine—Discomfort—Methylprednisolone—multiple sclerosis	0.0013	0.00143	CcSEcCtD
Apraclonidine—Headache—Azathioprine—multiple sclerosis	0.0013	0.00142	CcSEcCtD
Apraclonidine—Dry mouth—Triamcinolone—multiple sclerosis	0.00129	0.00141	CcSEcCtD
Apraclonidine—Angiopathy—Prednisone—multiple sclerosis	0.00127	0.0014	CcSEcCtD
Apraclonidine—Conjunctivitis—Methotrexate—multiple sclerosis	0.00127	0.00139	CcSEcCtD
Apraclonidine—Malaise—Betamethasone—multiple sclerosis	0.00127	0.00139	CcSEcCtD
Apraclonidine—Malaise—Dexamethasone—multiple sclerosis	0.00127	0.00139	CcSEcCtD
Apraclonidine—Oedema—Triamcinolone—multiple sclerosis	0.00126	0.00139	CcSEcCtD
Apraclonidine—Syncope—Betamethasone—multiple sclerosis	0.00126	0.00138	CcSEcCtD
Apraclonidine—Syncope—Dexamethasone—multiple sclerosis	0.00126	0.00138	CcSEcCtD
Apraclonidine—Arrhythmia—Prednisone—multiple sclerosis	0.00125	0.00138	CcSEcCtD
Apraclonidine—Infection—Triamcinolone—multiple sclerosis	0.00125	0.00138	CcSEcCtD
Apraclonidine—Infection—Methylprednisolone—multiple sclerosis	0.00125	0.00137	CcSEcCtD
Apraclonidine—Insomnia—Prednisolone—multiple sclerosis	0.00124	0.00136	CcSEcCtD
Apraclonidine—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.00124	0.00136	CcSEcCtD
Apraclonidine—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.00123	0.00135	CcSEcCtD
Apraclonidine—Paraesthesia—Prednisolone—multiple sclerosis	0.00123	0.00135	CcSEcCtD
Apraclonidine—Mental disorder—Prednisone—multiple sclerosis	0.00123	0.00135	CcSEcCtD
Apraclonidine—Nausea—Azathioprine—multiple sclerosis	0.00123	0.00135	CcSEcCtD
Apraclonidine—Skin disorder—Methylprednisolone—multiple sclerosis	0.00122	0.00134	CcSEcCtD
Apraclonidine—Erythema—Prednisone—multiple sclerosis	0.00122	0.00134	CcSEcCtD
Apraclonidine—Asthenia—Mitoxantrone—multiple sclerosis	0.0012	0.00132	CcSEcCtD
Apraclonidine—Myalgia—Betamethasone—multiple sclerosis	0.0012	0.00131	CcSEcCtD
Apraclonidine—Myalgia—Dexamethasone—multiple sclerosis	0.0012	0.00131	CcSEcCtD
Apraclonidine—Discomfort—Betamethasone—multiple sclerosis	0.00118	0.0013	CcSEcCtD
Apraclonidine—Discomfort—Dexamethasone—multiple sclerosis	0.00118	0.0013	CcSEcCtD
Apraclonidine—Pain—Prednisolone—multiple sclerosis	0.00117	0.00129	CcSEcCtD
Apraclonidine—Haemorrhage—Methotrexate—multiple sclerosis	0.00117	0.00129	CcSEcCtD
Apraclonidine—Pharyngitis—Methotrexate—multiple sclerosis	0.00116	0.00128	CcSEcCtD
Apraclonidine—Vision blurred—Prednisone—multiple sclerosis	0.00115	0.00126	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	0.00115	0.00126	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	0.00115	0.00126	CcSEcCtD
Apraclonidine—Oedema—Betamethasone—multiple sclerosis	0.00115	0.00126	CcSEcCtD
Apraclonidine—Oedema—Dexamethasone—multiple sclerosis	0.00115	0.00126	CcSEcCtD
Apraclonidine—Diarrhoea—Mitoxantrone—multiple sclerosis	0.00115	0.00126	CcSEcCtD
Apraclonidine—Insomnia—Triamcinolone—multiple sclerosis	0.00114	0.00125	CcSEcCtD
Apraclonidine—Insomnia—Methylprednisolone—multiple sclerosis	0.00114	0.00125	CcSEcCtD
Apraclonidine—Infection—Dexamethasone—multiple sclerosis	0.00114	0.00125	CcSEcCtD
Apraclonidine—Infection—Betamethasone—multiple sclerosis	0.00114	0.00125	CcSEcCtD
Apraclonidine—Ill-defined disorder—Prednisone—multiple sclerosis	0.00113	0.00125	CcSEcCtD
Apraclonidine—Paraesthesia—Triamcinolone—multiple sclerosis	0.00113	0.00124	CcSEcCtD
Apraclonidine—Feeling abnormal—Prednisolone—multiple sclerosis	0.00113	0.00124	CcSEcCtD
Apraclonidine—Paraesthesia—Methylprednisolone—multiple sclerosis	0.00113	0.00124	CcSEcCtD
Apraclonidine—Visual impairment—Methotrexate—multiple sclerosis	0.00113	0.00124	CcSEcCtD
Apraclonidine—Dyspnoea—Triamcinolone—multiple sclerosis	0.00113	0.00124	CcSEcCtD
Apraclonidine—Nervous system disorder—Betamethasone—multiple sclerosis	0.00112	0.00123	CcSEcCtD
Apraclonidine—Nervous system disorder—Dexamethasone—multiple sclerosis	0.00112	0.00123	CcSEcCtD
Apraclonidine—Malaise—Prednisone—multiple sclerosis	0.0011	0.00121	CcSEcCtD
Apraclonidine—Eye disorder—Methotrexate—multiple sclerosis	0.0011	0.0012	CcSEcCtD
Apraclonidine—Syncope—Prednisone—multiple sclerosis	0.0011	0.0012	CcSEcCtD
Apraclonidine—Fatigue—Triamcinolone—multiple sclerosis	0.00109	0.00119	CcSEcCtD
Apraclonidine—Fatigue—Methylprednisolone—multiple sclerosis	0.00109	0.00119	CcSEcCtD
Apraclonidine—Pain—Triamcinolone—multiple sclerosis	0.00108	0.00119	CcSEcCtD
Apraclonidine—Angiopathy—Methotrexate—multiple sclerosis	0.00106	0.00117	CcSEcCtD
Apraclonidine—Vomiting—Mitoxantrone—multiple sclerosis	0.00106	0.00117	CcSEcCtD
Apraclonidine—Mediastinal disorder—Methotrexate—multiple sclerosis	0.00106	0.00116	CcSEcCtD
Apraclonidine—Dermatitis—Mitoxantrone—multiple sclerosis	0.00105	0.00116	CcSEcCtD
Apraclonidine—Headache—Mitoxantrone—multiple sclerosis	0.00105	0.00115	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	0.00104	0.00115	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	0.00104	0.00115	CcSEcCtD
Apraclonidine—Myalgia—Prednisone—multiple sclerosis	0.00104	0.00114	CcSEcCtD
Apraclonidine—Feeling abnormal—Triamcinolone—multiple sclerosis	0.00104	0.00114	CcSEcCtD
Apraclonidine—Feeling abnormal—Methylprednisolone—multiple sclerosis	0.00104	0.00114	CcSEcCtD
Apraclonidine—Insomnia—Betamethasone—multiple sclerosis	0.00104	0.00114	CcSEcCtD
Apraclonidine—Insomnia—Dexamethasone—multiple sclerosis	0.00104	0.00114	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.00103	0.00113	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.00103	0.00113	CcSEcCtD
Apraclonidine—Paraesthesia—Dexamethasone—multiple sclerosis	0.00103	0.00113	CcSEcCtD
Apraclonidine—Paraesthesia—Betamethasone—multiple sclerosis	0.00103	0.00113	CcSEcCtD
Apraclonidine—Discomfort—Prednisone—multiple sclerosis	0.00103	0.00113	CcSEcCtD
Apraclonidine—Mental disorder—Methotrexate—multiple sclerosis	0.00103	0.00113	CcSEcCtD
Apraclonidine—Erythema—Methotrexate—multiple sclerosis	0.00102	0.00112	CcSEcCtD
Apraclonidine—Hypersensitivity—Prednisolone—multiple sclerosis	0.00101	0.00111	CcSEcCtD
Apraclonidine—Dysgeusia—Methotrexate—multiple sclerosis	0.001	0.0011	CcSEcCtD
Apraclonidine—Oedema—Prednisone—multiple sclerosis	0.000998	0.0011	CcSEcCtD
Apraclonidine—Abdominal pain—Methylprednisolone—multiple sclerosis	0.000996	0.00109	CcSEcCtD
Apraclonidine—Nausea—Mitoxantrone—multiple sclerosis	0.000994	0.00109	CcSEcCtD
Apraclonidine—Infection—Prednisone—multiple sclerosis	0.000991	0.00109	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000989	0.00109	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000989	0.00109	CcSEcCtD
Apraclonidine—Fatigue—Dexamethasone—multiple sclerosis	0.000988	0.00108	CcSEcCtD
Apraclonidine—Fatigue—Betamethasone—multiple sclerosis	0.000988	0.00108	CcSEcCtD
Apraclonidine—Pain—Betamethasone—multiple sclerosis	0.00098	0.00108	CcSEcCtD
Apraclonidine—Pain—Dexamethasone—multiple sclerosis	0.00098	0.00108	CcSEcCtD
Apraclonidine—Nervous system disorder—Prednisone—multiple sclerosis	0.000978	0.00107	CcSEcCtD
Apraclonidine—Skin disorder—Prednisone—multiple sclerosis	0.000969	0.00106	CcSEcCtD
Apraclonidine—Vision blurred—Methotrexate—multiple sclerosis	0.000963	0.00106	CcSEcCtD
Apraclonidine—Ill-defined disorder—Methotrexate—multiple sclerosis	0.000948	0.00104	CcSEcCtD
Apraclonidine—Feeling abnormal—Dexamethasone—multiple sclerosis	0.000944	0.00104	CcSEcCtD
Apraclonidine—Feeling abnormal—Betamethasone—multiple sclerosis	0.000944	0.00104	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Dexamethasone—multiple sclerosis	0.000937	0.00103	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Betamethasone—multiple sclerosis	0.000937	0.00103	CcSEcCtD
Apraclonidine—Hypersensitivity—Triamcinolone—multiple sclerosis	0.00093	0.00102	CcSEcCtD
Apraclonidine—Hypersensitivity—Methylprednisolone—multiple sclerosis	0.000928	0.00102	CcSEcCtD
Apraclonidine—Malaise—Methotrexate—multiple sclerosis	0.000921	0.00101	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Prednisone—multiple sclerosis	0.000909	0.000998	CcSEcCtD
Apraclonidine—Dizziness—Prednisolone—multiple sclerosis	0.000908	0.000997	CcSEcCtD
Apraclonidine—Asthenia—Triamcinolone—multiple sclerosis	0.000906	0.000994	CcSEcCtD
Apraclonidine—Abdominal pain—Dexamethasone—multiple sclerosis	0.000906	0.000994	CcSEcCtD
Apraclonidine—Abdominal pain—Betamethasone—multiple sclerosis	0.000906	0.000994	CcSEcCtD
Apraclonidine—Asthenia—Methylprednisolone—multiple sclerosis	0.000904	0.000992	CcSEcCtD
Apraclonidine—Insomnia—Prednisone—multiple sclerosis	0.000902	0.000991	CcSEcCtD
Apraclonidine—Paraesthesia—Prednisone—multiple sclerosis	0.000896	0.000983	CcSEcCtD
Apraclonidine—Pruritus—Triamcinolone—multiple sclerosis	0.000893	0.000981	CcSEcCtD
Apraclonidine—Pruritus—Methylprednisolone—multiple sclerosis	0.000891	0.000978	CcSEcCtD
Apraclonidine—Myalgia—Methotrexate—multiple sclerosis	0.00087	0.000955	CcSEcCtD
Apraclonidine—Chest pain—Methotrexate—multiple sclerosis	0.00087	0.000955	CcSEcCtD
Apraclonidine—Dermatitis—Prednisolone—multiple sclerosis	0.000865	0.000949	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	0.000864	0.000948	CcSEcCtD
Apraclonidine—Diarrhoea—Methylprednisolone—multiple sclerosis	0.000862	0.000946	CcSEcCtD
Apraclonidine—Fatigue—Prednisone—multiple sclerosis	0.00086	0.000944	CcSEcCtD
Apraclonidine—Headache—Prednisolone—multiple sclerosis	0.00086	0.000944	CcSEcCtD
Apraclonidine—Discomfort—Methotrexate—multiple sclerosis	0.000859	0.000943	CcSEcCtD
Apraclonidine—Constipation—Prednisone—multiple sclerosis	0.000853	0.000937	CcSEcCtD
Apraclonidine—Dizziness—Triamcinolone—multiple sclerosis	0.000835	0.000917	CcSEcCtD
Apraclonidine—Dizziness—Methylprednisolone—multiple sclerosis	0.000833	0.000914	CcSEcCtD
Apraclonidine—Infection—Methotrexate—multiple sclerosis	0.000828	0.000909	CcSEcCtD
Apraclonidine—Feeling abnormal—Prednisone—multiple sclerosis	0.000822	0.000902	CcSEcCtD
Apraclonidine—Asthenia—Betamethasone—multiple sclerosis	0.000822	0.000902	CcSEcCtD
Apraclonidine—Asthenia—Dexamethasone—multiple sclerosis	0.000822	0.000902	CcSEcCtD
Apraclonidine—Nervous system disorder—Methotrexate—multiple sclerosis	0.000818	0.000898	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Prednisone—multiple sclerosis	0.000816	0.000896	CcSEcCtD
Apraclonidine—Nausea—Prednisolone—multiple sclerosis	0.000816	0.000895	CcSEcCtD
Apraclonidine—Pruritus—Dexamethasone—multiple sclerosis	0.000811	0.00089	CcSEcCtD
Apraclonidine—Pruritus—Betamethasone—multiple sclerosis	0.000811	0.00089	CcSEcCtD
Apraclonidine—Skin disorder—Methotrexate—multiple sclerosis	0.00081	0.000889	CcSEcCtD
Apraclonidine—Vomiting—Triamcinolone—multiple sclerosis	0.000803	0.000881	CcSEcCtD
Apraclonidine—Vomiting—Methylprednisolone—multiple sclerosis	0.000801	0.000879	CcSEcCtD
Apraclonidine—Dermatitis—Triamcinolone—multiple sclerosis	0.000795	0.000873	CcSEcCtD
Apraclonidine—Dermatitis—Methylprednisolone—multiple sclerosis	0.000794	0.000871	CcSEcCtD
Apraclonidine—Headache—Triamcinolone—multiple sclerosis	0.000791	0.000868	CcSEcCtD
Apraclonidine—Headache—Methylprednisolone—multiple sclerosis	0.000789	0.000866	CcSEcCtD
Apraclonidine—Abdominal pain—Prednisone—multiple sclerosis	0.000789	0.000866	CcSEcCtD
Apraclonidine—Diarrhoea—Dexamethasone—multiple sclerosis	0.000784	0.00086	CcSEcCtD
Apraclonidine—Diarrhoea—Betamethasone—multiple sclerosis	0.000784	0.00086	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	0.00076	0.000834	CcSEcCtD
Apraclonidine—Dizziness—Betamethasone—multiple sclerosis	0.000758	0.000832	CcSEcCtD
Apraclonidine—Dizziness—Dexamethasone—multiple sclerosis	0.000758	0.000832	CcSEcCtD
Apraclonidine—Insomnia—Methotrexate—multiple sclerosis	0.000754	0.000828	CcSEcCtD
Apraclonidine—Nausea—Triamcinolone—multiple sclerosis	0.00075	0.000823	CcSEcCtD
Apraclonidine—Paraesthesia—Methotrexate—multiple sclerosis	0.000749	0.000822	CcSEcCtD
Apraclonidine—Nausea—Methylprednisolone—multiple sclerosis	0.000748	0.000821	CcSEcCtD
Apraclonidine—Dyspnoea—Methotrexate—multiple sclerosis	0.000743	0.000816	CcSEcCtD
Apraclonidine—Somnolence—Methotrexate—multiple sclerosis	0.000741	0.000814	CcSEcCtD
Apraclonidine—Hypersensitivity—Prednisone—multiple sclerosis	0.000735	0.000807	CcSEcCtD
Apraclonidine—Vomiting—Dexamethasone—multiple sclerosis	0.000728	0.0008	CcSEcCtD
Apraclonidine—Vomiting—Betamethasone—multiple sclerosis	0.000728	0.0008	CcSEcCtD
Apraclonidine—Dermatitis—Dexamethasone—multiple sclerosis	0.000722	0.000792	CcSEcCtD
Apraclonidine—Dermatitis—Betamethasone—multiple sclerosis	0.000722	0.000792	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Methotrexate—multiple sclerosis	0.00072	0.00079	CcSEcCtD
Apraclonidine—Fatigue—Methotrexate—multiple sclerosis	0.000719	0.000789	CcSEcCtD
Apraclonidine—Headache—Betamethasone—multiple sclerosis	0.000718	0.000788	CcSEcCtD
Apraclonidine—Headache—Dexamethasone—multiple sclerosis	0.000718	0.000788	CcSEcCtD
Apraclonidine—Asthenia—Prednisone—multiple sclerosis	0.000716	0.000786	CcSEcCtD
Apraclonidine—Pain—Methotrexate—multiple sclerosis	0.000713	0.000783	CcSEcCtD
Apraclonidine—Pruritus—Prednisone—multiple sclerosis	0.000706	0.000775	CcSEcCtD
Apraclonidine—Feeling abnormal—Methotrexate—multiple sclerosis	0.000687	0.000754	CcSEcCtD
Apraclonidine—Diarrhoea—Prednisone—multiple sclerosis	0.000683	0.000749	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Methotrexate—multiple sclerosis	0.000682	0.000748	CcSEcCtD
Apraclonidine—Nausea—Betamethasone—multiple sclerosis	0.000681	0.000747	CcSEcCtD
Apraclonidine—Nausea—Dexamethasone—multiple sclerosis	0.000681	0.000747	CcSEcCtD
Apraclonidine—Dizziness—Prednisone—multiple sclerosis	0.00066	0.000724	CcSEcCtD
Apraclonidine—Abdominal pain—Methotrexate—multiple sclerosis	0.000659	0.000724	CcSEcCtD
Apraclonidine—Vomiting—Prednisone—multiple sclerosis	0.000634	0.000696	CcSEcCtD
Apraclonidine—Dermatitis—Prednisone—multiple sclerosis	0.000629	0.00069	CcSEcCtD
Apraclonidine—Headache—Prednisone—multiple sclerosis	0.000625	0.000686	CcSEcCtD
Apraclonidine—Hypersensitivity—Methotrexate—multiple sclerosis	0.000614	0.000674	CcSEcCtD
Apraclonidine—Asthenia—Methotrexate—multiple sclerosis	0.000598	0.000657	CcSEcCtD
Apraclonidine—Nausea—Prednisone—multiple sclerosis	0.000593	0.000651	CcSEcCtD
Apraclonidine—Pruritus—Methotrexate—multiple sclerosis	0.00059	0.000648	CcSEcCtD
Apraclonidine—Diarrhoea—Methotrexate—multiple sclerosis	0.000571	0.000626	CcSEcCtD
Apraclonidine—Dizziness—Methotrexate—multiple sclerosis	0.000551	0.000605	CcSEcCtD
Apraclonidine—Vomiting—Methotrexate—multiple sclerosis	0.00053	0.000582	CcSEcCtD
Apraclonidine—Dermatitis—Methotrexate—multiple sclerosis	0.000525	0.000577	CcSEcCtD
Apraclonidine—Headache—Methotrexate—multiple sclerosis	0.000522	0.000573	CcSEcCtD
Apraclonidine—Nausea—Methotrexate—multiple sclerosis	0.000495	0.000544	CcSEcCtD
Apraclonidine—ADRA1A—Signaling Pathways—S1PR1—multiple sclerosis	0.000116	0.0013	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—GPR65—multiple sclerosis	0.000114	0.00129	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—CCR2—multiple sclerosis	0.000114	0.00128	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—PTGER4—multiple sclerosis	0.000113	0.00128	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—GPC5—multiple sclerosis	0.000113	0.00127	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—RGS1—multiple sclerosis	0.000113	0.00127	CbGpPWpGaD
Apraclonidine—ADRA2B—Platelet activation, signaling and aggregation—TGFB1—multiple sclerosis	0.000112	0.00126	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR ligand binding—POMC—multiple sclerosis	0.000112	0.00126	CbGpPWpGaD
Apraclonidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—POMC—multiple sclerosis	0.000112	0.00126	CbGpPWpGaD
Apraclonidine—ADRA2B—Platelet activation, signaling and aggregation—MAPK1—multiple sclerosis	0.00011	0.00124	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—CXCR3—multiple sclerosis	0.00011	0.00123	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR ligand binding—CCL2—multiple sclerosis	0.00011	0.00123	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—PTGER4—multiple sclerosis	0.000109	0.00123	CbGpPWpGaD
Apraclonidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	0.000109	0.00123	CbGpPWpGaD
Apraclonidine—ADRA2A—Platelet activation, signaling and aggregation—IL2—multiple sclerosis	0.000109	0.00123	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR ligand binding—CCR5—multiple sclerosis	0.000109	0.00122	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—CNR1—multiple sclerosis	0.000108	0.00122	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—S1PR1—multiple sclerosis	0.000108	0.00121	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—GPR65—multiple sclerosis	0.000107	0.0012	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—CCR2—multiple sclerosis	0.000107	0.0012	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—CXCR3—multiple sclerosis	0.000106	0.00119	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—CNR1—multiple sclerosis	0.000105	0.00118	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—GPC5—multiple sclerosis	0.000105	0.00118	CbGpPWpGaD
Apraclonidine—ADRA2C—Platelet activation, signaling and aggregation—TGFB1—multiple sclerosis	0.000105	0.00118	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CCR1—multiple sclerosis	0.000105	0.00118	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CXCL13—multiple sclerosis	0.000105	0.00118	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR ligand binding—POMC—multiple sclerosis	0.000105	0.00118	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—CXCL10—multiple sclerosis	0.000104	0.00117	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—RRM1—multiple sclerosis	0.000104	0.00117	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—CCL3—multiple sclerosis	0.000103	0.00116	CbGpPWpGaD
Apraclonidine—ADRA2C—Platelet activation, signaling and aggregation—MAPK1—multiple sclerosis	0.000103	0.00115	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—CCR2—multiple sclerosis	0.000103	0.00115	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR ligand binding—CCL2—multiple sclerosis	0.000102	0.00115	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—PTGER4—multiple sclerosis	0.000102	0.00114	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—PTGER4—multiple sclerosis	9.92e-05	0.00112	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—RGS1—multiple sclerosis	9.86e-05	0.00111	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—CNR1—multiple sclerosis	9.84e-05	0.00111	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—CXCR3—multiple sclerosis	9.8e-05	0.0011	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CXCL13—multiple sclerosis	9.77e-05	0.0011	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CCR1—multiple sclerosis	9.77e-05	0.0011	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—CXCL10—multiple sclerosis	9.76e-05	0.0011	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—IL2RA—multiple sclerosis	9.58e-05	0.00108	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—CXCR3—multiple sclerosis	9.58e-05	0.00108	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—CCL3—multiple sclerosis	9.58e-05	0.00108	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—CCR2—multiple sclerosis	9.54e-05	0.00107	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—CXCL10—multiple sclerosis	9.49e-05	0.00107	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—CNR1—multiple sclerosis	9.47e-05	0.00107	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—GPR65—multiple sclerosis	9.34e-05	0.00105	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—CCR2—multiple sclerosis	9.32e-05	0.00105	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—PTGER4—multiple sclerosis	9.22e-05	0.00104	CbGpPWpGaD
Apraclonidine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—multiple sclerosis	9.17e-05	0.00103	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—RGS1—multiple sclerosis	9.16e-05	0.00103	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR ligand binding—POMC—multiple sclerosis	9.15e-05	0.00103	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—ALB—multiple sclerosis	9.13e-05	0.00103	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—CCL5—multiple sclerosis	8.99e-05	0.00101	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR ligand binding—CCL2—multiple sclerosis	8.95e-05	0.00101	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—CXCR3—multiple sclerosis	8.9e-05	0.001	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—CXCL10—multiple sclerosis	8.86e-05	0.000996	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—CNR1—multiple sclerosis	8.8e-05	0.00099	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—GPR65—multiple sclerosis	8.68e-05	0.000976	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—CCR2—multiple sclerosis	8.66e-05	0.000974	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—CNR1—multiple sclerosis	8.6e-05	0.000967	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CCR1—multiple sclerosis	8.55e-05	0.000961	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CXCL13—multiple sclerosis	8.55e-05	0.000961	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—ALB—multiple sclerosis	8.53e-05	0.000959	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—CXCL10—multiple sclerosis	8.53e-05	0.000959	CbGpPWpGaD
Apraclonidine—ADRA2A—Platelet activation, signaling and aggregation—TGFB1—multiple sclerosis	8.5e-05	0.000956	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR ligand binding—POMC—multiple sclerosis	8.5e-05	0.000956	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—CCL5—multiple sclerosis	8.4e-05	0.000944	CbGpPWpGaD
Apraclonidine—ADRA2A—Platelet activation, signaling and aggregation—MAPK1—multiple sclerosis	8.34e-05	0.000938	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR ligand binding—CCL2—multiple sclerosis	8.32e-05	0.000935	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—CCL5—multiple sclerosis	8.16e-05	0.000918	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—CCR5—multiple sclerosis	8.1e-05	0.000911	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—CNR1—multiple sclerosis	7.99e-05	0.000899	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—IL2RA—multiple sclerosis	7.98e-05	0.000898	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CXCL13—multiple sclerosis	7.94e-05	0.000893	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CCR1—multiple sclerosis	7.94e-05	0.000893	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—CXCL10—multiple sclerosis	7.92e-05	0.000891	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—CXCL10—multiple sclerosis	7.75e-05	0.000871	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—CCL5—multiple sclerosis	7.63e-05	0.000858	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—CCR5—multiple sclerosis	7.57e-05	0.000851	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—IL2RA—multiple sclerosis	7.46e-05	0.000839	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CCL3—multiple sclerosis	7.46e-05	0.000838	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—IL2—multiple sclerosis	7.41e-05	0.000833	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—CCR5—multiple sclerosis	7.36e-05	0.000827	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—CCL5—multiple sclerosis	7.34e-05	0.000826	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—BCHE—multiple sclerosis	7.34e-05	0.000825	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—IL2RA—multiple sclerosis	7.25e-05	0.000815	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—CXCL10—multiple sclerosis	7.2e-05	0.000809	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PTGER4—multiple sclerosis	7.18e-05	0.000807	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PGR—multiple sclerosis	7.07e-05	0.000795	CbGpPWpGaD
Apraclonidine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—multiple sclerosis	7.05e-05	0.000793	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CCL3—multiple sclerosis	6.97e-05	0.000783	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CXCR3—multiple sclerosis	6.93e-05	0.000779	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—ALB—multiple sclerosis	6.93e-05	0.000779	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—IL2—multiple sclerosis	6.92e-05	0.000778	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—CCR5—multiple sclerosis	6.87e-05	0.000773	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CD28—multiple sclerosis	6.87e-05	0.000772	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—CCL5—multiple sclerosis	6.82e-05	0.000767	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—IL2RA—multiple sclerosis	6.77e-05	0.000761	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CCR2—multiple sclerosis	6.74e-05	0.000758	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PTGER4—multiple sclerosis	6.7e-05	0.000754	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—CCL5—multiple sclerosis	6.67e-05	0.00075	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—CCR5—multiple sclerosis	6.61e-05	0.000744	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PGR—multiple sclerosis	6.6e-05	0.000742	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—IL2RA—multiple sclerosis	6.52e-05	0.000733	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CXCR3—multiple sclerosis	6.48e-05	0.000728	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CD28—multiple sclerosis	6.41e-05	0.000721	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—POMC—multiple sclerosis	6.33e-05	0.000712	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CCR2—multiple sclerosis	6.3e-05	0.000708	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CNR1—multiple sclerosis	6.22e-05	0.0007	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—CCL5—multiple sclerosis	6.19e-05	0.000697	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—CCR5—multiple sclerosis	6.15e-05	0.000691	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CCL3—multiple sclerosis	6.09e-05	0.000685	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—IL2RA—multiple sclerosis	6.06e-05	0.000681	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—CCR5—multiple sclerosis	6.01e-05	0.000675	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—BCHE—multiple sclerosis	5.96e-05	0.000671	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—IL2RA—multiple sclerosis	5.92e-05	0.000666	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—POMC—multiple sclerosis	5.91e-05	0.000665	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PTGER4—multiple sclerosis	5.86e-05	0.000659	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CNR1—multiple sclerosis	5.81e-05	0.000654	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—TGFB1—multiple sclerosis	5.78e-05	0.00065	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PGR—multiple sclerosis	5.77e-05	0.000649	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—POMC—multiple sclerosis	5.75e-05	0.000646	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—MAPK1—multiple sclerosis	5.67e-05	0.000637	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CXCR3—multiple sclerosis	5.66e-05	0.000637	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CCL3—multiple sclerosis	5.66e-05	0.000636	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—CCL2—multiple sclerosis	5.63e-05	0.000633	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—IL2—multiple sclerosis	5.62e-05	0.000632	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CD28—multiple sclerosis	5.61e-05	0.000631	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CXCL10—multiple sclerosis	5.6e-05	0.00063	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—CCR5—multiple sclerosis	5.58e-05	0.000628	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CCR2—multiple sclerosis	5.51e-05	0.000619	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—IL2RA—multiple sclerosis	5.5e-05	0.000619	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PTGER4—multiple sclerosis	5.45e-05	0.000612	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—TGFB1—multiple sclerosis	5.4e-05	0.000607	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—POMC—multiple sclerosis	5.37e-05	0.000604	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PGR—multiple sclerosis	5.36e-05	0.000603	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—MAPK1—multiple sclerosis	5.29e-05	0.000595	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CXCR3—multiple sclerosis	5.26e-05	0.000591	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—CCL2—multiple sclerosis	5.25e-05	0.000591	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CXCL10—multiple sclerosis	5.23e-05	0.000589	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CD28—multiple sclerosis	5.21e-05	0.000586	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—POMC—multiple sclerosis	5.17e-05	0.000581	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CCR2—multiple sclerosis	5.12e-05	0.000575	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—TYK2—multiple sclerosis	5.11e-05	0.000574	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CNR1—multiple sclerosis	5.08e-05	0.000571	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CD86—multiple sclerosis	4.9e-05	0.000551	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CCL5—multiple sclerosis	4.82e-05	0.000542	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—POMC—multiple sclerosis	4.8e-05	0.00054	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—TYK2—multiple sclerosis	4.77e-05	0.000537	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CNR1—multiple sclerosis	4.72e-05	0.000531	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—POMC—multiple sclerosis	4.69e-05	0.000528	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—IL2—multiple sclerosis	4.68e-05	0.000526	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—CCL2—multiple sclerosis	4.59e-05	0.000517	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CD86—multiple sclerosis	4.58e-05	0.000515	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CXCL10—multiple sclerosis	4.58e-05	0.000515	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CCL5—multiple sclerosis	4.51e-05	0.000507	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—SPP1—multiple sclerosis	4.47e-05	0.000502	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—APOE—multiple sclerosis	4.42e-05	0.000497	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—TGFB1—multiple sclerosis	4.38e-05	0.000493	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—IL2—multiple sclerosis	4.37e-05	0.000492	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—POMC—multiple sclerosis	4.36e-05	0.00049	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CCR5—multiple sclerosis	4.35e-05	0.000489	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—MAPK1—multiple sclerosis	4.3e-05	0.000483	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—IL2RA—multiple sclerosis	4.28e-05	0.000482	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—CCL2—multiple sclerosis	4.27e-05	0.00048	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CXCL10—multiple sclerosis	4.25e-05	0.000478	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—IL2—multiple sclerosis	4.25e-05	0.000478	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—SPP1—multiple sclerosis	4.17e-05	0.000469	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—TYK2—multiple sclerosis	4.17e-05	0.000469	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CCR5—multiple sclerosis	4.06e-05	0.000456	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CD86—multiple sclerosis	4e-05	0.00045	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—IL2RA—multiple sclerosis	4e-05	0.00045	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—IL2—multiple sclerosis	3.97e-05	0.000446	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—APOE—multiple sclerosis	3.95e-05	0.000445	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CCL5—multiple sclerosis	3.94e-05	0.000443	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—TYK2—multiple sclerosis	3.88e-05	0.000436	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—IL2—multiple sclerosis	3.82e-05	0.00043	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—POMC—multiple sclerosis	3.79e-05	0.000427	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CD86—multiple sclerosis	3.72e-05	0.000418	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—APOE—multiple sclerosis	3.69e-05	0.000415	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CCL5—multiple sclerosis	3.66e-05	0.000412	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—SPP1—multiple sclerosis	3.65e-05	0.00041	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—APOE—multiple sclerosis	3.59e-05	0.000403	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CD80—multiple sclerosis	3.57e-05	0.000402	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—IL2—multiple sclerosis	3.55e-05	0.000399	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CCR5—multiple sclerosis	3.55e-05	0.000399	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—IL2RA—multiple sclerosis	3.5e-05	0.000393	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—IL2—multiple sclerosis	3.47e-05	0.00039	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—ALB—multiple sclerosis	3.46e-05	0.000389	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—POMC—multiple sclerosis	3.4e-05	0.000382	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—SPP1—multiple sclerosis	3.39e-05	0.000381	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CD80—multiple sclerosis	3.34e-05	0.000375	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CCL2—multiple sclerosis	3.32e-05	0.000374	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CCR5—multiple sclerosis	3.3e-05	0.000371	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—MAPK1—multiple sclerosis	3.25e-05	0.000366	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—IL2RA—multiple sclerosis	3.25e-05	0.000365	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—APOE—multiple sclerosis	3.23e-05	0.000363	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—IL2—multiple sclerosis	3.22e-05	0.000363	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—POMC—multiple sclerosis	3.17e-05	0.000357	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CCL2—multiple sclerosis	3.1e-05	0.000349	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—POMC—multiple sclerosis	3.08e-05	0.000347	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—MAPK1—multiple sclerosis	3.04e-05	0.000341	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—TYK2—multiple sclerosis	3.02e-05	0.000339	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—APOE—multiple sclerosis	3e-05	0.000337	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CD80—multiple sclerosis	2.92e-05	0.000328	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—TYK2—multiple sclerosis	2.82e-05	0.000317	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—ALB—multiple sclerosis	2.81e-05	0.000316	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—POMC—multiple sclerosis	2.77e-05	0.000312	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CCL2—multiple sclerosis	2.71e-05	0.000305	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CD80—multiple sclerosis	2.71e-05	0.000305	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—MAPK1—multiple sclerosis	2.65e-05	0.000299	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—POMC—multiple sclerosis	2.58e-05	0.00029	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CCL2—multiple sclerosis	2.52e-05	0.000283	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—IL2—multiple sclerosis	2.51e-05	0.000282	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—IL6—multiple sclerosis	2.5e-05	0.000281	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—MAPK1—multiple sclerosis	2.47e-05	0.000277	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—TYK2—multiple sclerosis	2.46e-05	0.000277	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—MMP9—multiple sclerosis	2.38e-05	0.000267	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—IL2—multiple sclerosis	2.35e-05	0.000264	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—IL6—multiple sclerosis	2.33e-05	0.000262	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—TYK2—multiple sclerosis	2.29e-05	0.000257	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—MMP9—multiple sclerosis	2.22e-05	0.00025	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—STAT3—multiple sclerosis	2.11e-05	0.000238	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—IL2—multiple sclerosis	2.05e-05	0.000231	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—IL6—multiple sclerosis	2.04e-05	0.000229	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—STAT3—multiple sclerosis	1.97e-05	0.000222	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—MYC—multiple sclerosis	1.96e-05	0.000221	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—TGFB1—multiple sclerosis	1.96e-05	0.00022	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—MMP9—multiple sclerosis	1.94e-05	0.000218	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—MAPK1—multiple sclerosis	1.92e-05	0.000216	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—IL2—multiple sclerosis	1.9e-05	0.000214	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—IL6—multiple sclerosis	1.9e-05	0.000213	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—MYC—multiple sclerosis	1.83e-05	0.000206	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—TGFB1—multiple sclerosis	1.83e-05	0.000206	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—MMP9—multiple sclerosis	1.8e-05	0.000203	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—MAPK1—multiple sclerosis	1.79e-05	0.000202	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—STAT3—multiple sclerosis	1.73e-05	0.000194	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—MYC—multiple sclerosis	1.6e-05	0.00018	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—STAT3—multiple sclerosis	1.6e-05	0.00018	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—TGFB1—multiple sclerosis	1.6e-05	0.00018	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—MAPK1—multiple sclerosis	1.57e-05	0.000176	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—MYC—multiple sclerosis	1.49e-05	0.000167	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—TGFB1—multiple sclerosis	1.49e-05	0.000167	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—IL6—multiple sclerosis	1.48e-05	0.000166	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—MAPK1—multiple sclerosis	1.46e-05	0.000164	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—IL6—multiple sclerosis	1.38e-05	0.000155	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—IL6—multiple sclerosis	1.21e-05	0.000136	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—IL6—multiple sclerosis	1.12e-05	0.000126	CbGpPWpGaD
